


=>

Uploading C:\Program Files\Stnexp\Queries\10543014-amended.str




```
ring nodes :  
1 2 3 4 5 6 7 8  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 7-8  
exact/norm bonds :  
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 7-8  
isolated ring systems :  
containing 1 :
```

```
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom
```

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10543014-amended-narrow.str



```
chain nodes :  
1 3 4 5 6 7 8  
chain bonds :  
1-3 1-4 1-5 1-6 1-7 7-8  
exact/norm bonds :  
1-3 1-4 1-5 1-6 1-7 7-8
```

```
Connectivity :  
7:2 E exact RC ring/chain  
Match level :  
1:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS  
Generic attributes :  
1:  
Saturation : Saturated  
Number of Hetero Atoms : Exactly 1  
Type of Ring System : Polycyclic  
7:  
Saturation : Saturated
```

Element Count :
Node 1: Limited
N,N1
C,C7

L2 STRUCTURE UPLOADED

=> d his

FILE 'REGISTRY' ENTERED AT 06:26:52 ON 22 DEC 2008

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L4 10461 S L1 SSS FULL
L5 51 S L2 SSS FULL SUB=L4

FILE 'CAPLUS' ENTERED AT 06:27:51 ON 22 DEC 2008

L6 42 S L5
L9 1 S US200!-543014/APPS
L10 1 S L6 AND L9
L11 41 S L6 NOT L9

FILE 'REGISTRY' ENTERED AT 06:28:30 ON 22 DEC 2008


=> d l1

L1 HAS NO ANSWERS
L1 STR



=> d l2

L2 HAS NO ANSWERS
L2 STR



=> fil caplus

=> d l10 bib abs

✓L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN - INSTANT

PA	Molecularnature Limited, UK	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004064715	A2	20040805	WO 2004-GB198	20040121	
	WO 2004064715	A3	20041223			
	AU 2004206085	A1	20040805	AU 2004-206085	20040121	
	CA 2513881	A1	20040805	CA 2004-2513881	20040121	
	EP 1587480	A2	20051026	EP 2004-703841	20040121	
	CN 1761666	A	20060419	CN 2004-80007408	20040121	
	JP 2006515357	T	20060525	JP 2006-500223	20040121	
	IN 2005DN03195	A	20070413	IN 2005-DN3195	20050719	
	US 20070155814	A1	20070705	US 2006-543014	20060815	<--
PRAI	GB 2003-1554	A	20030123			
	WO 2004-GB198	A	20040121			

=> d l11 tot bib abs hitstr

✓L11 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

IN	Muller, Rolf; Muller-Cohn, Judy	PA	USA	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080268514	A1	20081030	US 2008-108360	20080423			
PRAI	US 2007-913781P	P	✓20070424					

L11 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

SO e-EROS Encyclopedia of Reagents for Organic Synthesis (2001), No pp. given
 Publisher: John Wiley & Sons, Ltd., Chichester, UK.
 CODEN: 69KUHI

URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/104554785/HOME>
 DT Conference; General Review; (online computer file)

LA English

OS CASREACT 149:306596

AB A review of the article (R)-(-)-2,2-Diphenylcyclopentanol.

IT 159440-57-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

((R)-(-)-2,2-Diphenylcyclopentanol)

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-,
 (1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



✓L11 ANSWER 3 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

PA	Biomatrica, Inc., USA				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080176209	A1	20080724	US 2007-876667	20071022
	US 20050276728	A1	20051215	US 2005-102588	20050408
	US 20060099567	A1	20060511	US 2005-291267	20051201
	WO 2007075253	A2	20070705	WO 2006-US45661	20061129
	WO 2007075253	A3	20080103		
	US 20080307117	A1	20081211	US 2008-182926	20080730
PRAI	US 2004-560829P	P	√20040408		
	US 2005-102588	A2	20050408		
	US 2005-291267	A2	20051201		
	WO 2006-US45661	A2	20061129		
	US 2007-947275P	P	20070629		
	WO 2005-US12084	A2	20050408		

√L11 ANSWER 4 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Organic Letters (2008), 10(13), 2769-2771

√L11 ANSWER 5 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Tetrahedron (2008), 64(21), 4868-4879

√L11 ANSWER 6 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 PA Institute of Chemistry, Chinese Academy of Sciences, Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 18pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	√DATE	APPLICATION NO.	DATE
PI	CN 101153040	A	20080402	CN 2006-10113357	20060925
PRAI	CN 2006-10113357		20060925		

√L11 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Natural Product Communications (2008), 3(1), 41-44

√L11 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Natural Product Communications (2008), 3(1), 31-33

√L11 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Natural Product Reports (2008), 25(1), 139-165

√L11 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

PA	Summit Corporation PLC, UK				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	-----	-----	-----	-----

PI WO 2008009894 A2 20080124 WO 2007-GB2597
 WO 2008009894 A3 20080619
 PRAI GB 2006-14098 A 20060715

√20070712

√L11 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Journal of Natural Products (2007), 70(6), 993-997

√L11 ANSWER 12 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Science of Synthesis (2006), 20b, 1065-1089

√L11 ANSWER 13 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Tetrahedron: Asymmetry (2006), 17(18), 2702-2712

√L11 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

PA MNL Pharma Limited, UK

SO PCT Int. Appl., 85 pp.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2006077427	A2	20060727	WO 2006-GB209	√20060120
WO 2006077427	A3	20060914		
PRAI GB 2005-1352	A	20050121		

√L11 ANSWER 15 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Journal of Carbohydrate Chemistry (2006), 25(2-3), 281-295

√L11 ANSWER 16 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

PA MNL Pharma Limited, UK

SO PCT Int. Appl., 40 pp.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2006067419	A2	20060629	WO 2005-GB4945	√20051220
WO 2006067419	A3	20070329		
PRAI GB 2004-27882	A	20041221		

√L11 ANSWER 17 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

PA Biomatrica, Inc., USA

SO U.S. Pat. Appl. Publ., 54 pp., Cont.-in-part of U.S. Ser. No. 102,588.
 CODEN: USXXCO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI US 20060099567	A1	20060511	US 2005-291267	20051201
US 2005113147	A2	20051201	WO 2005-US12084	20050408
WO 2005113147	A3	20060323		
US 20050276728	A1	20051215	US 2005-102588	20050408
AU 2006330034	A1	20070705	AU 2006-330034	20061129
CA 2632203	A1	20070705	CA 2006-2632203	20061129
WO 2007075253	A2	20070705	WO 2006-US45661	20061129

WO 2007075253	A3	20080103		
EP 1951868	A2	20080806	EP 2006-848927	20061129
US 20080176209	A1	20080724	US 2007-876667	20071022
MX 200807097	A	20080613	MX 2008-7097	20080530
IN 2008DN05146	A	20080808	IN 2008-DN5146	20080616
KR 2008085003	A	20080922	KR 2008-716123	20080701
US 20080307117	A1	20081211	US 2008-182926	20080730
PRAI US 2004-560829P	P	√20040408		
US 2005-102588	A2	20050408		
WO 2005-US12084	A2	20050408		
US 2005-291267	A	20051201		
WO 2006-US45661	W	20061129		
US 2007-947275P	P	20070629		

√_{L11} ANSWER 18 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Acta Crystallographica, Section E: Structure Reports Online (2006),
 E62(3), o928-o930

√_{L11} ANSWER 19 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 PA MNL Pharma Limited, UK
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2006008493 A1 20060126 WO 2005-GB2800 √20050718
 PRAI GB 2004-16419 A 20040723
 GB 2004-27926 A 20041221

√_{L11} ANSWER 20 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 PA M N L Pharma Limited, UK
 SO PCT Int. Appl., 91 pp.
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2005070418 A1 20050804 WO 2005-GB215 √20050121
 AU 2005205962 A1 20050804 AU 2005-205962 20050121
 CA 2553854 A1 20050804 CA 2005-2553854 20050121
 EP 1711176 A1 20061018 EP 2005-701978 20050121
 JP 2007518785 T 20070712 JP 2006-550281 20050121
 PRAI GB 2004-1238 A 20040121
 WO 2005-GB215 W 20050121

√_{L11} ANSWER 21 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 PA M N L Pharma Limited, UK
 SO PCT Int. Appl., 58 pp.
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2005070415 A1 20050804 WO 2005-GB228 √20050121
 AU 2005205968 A1 20050804 AU 2005-205968 20050121
 CA 2553986 A1 20050804 CA 2005-2553986 20050121
 EP 1711174 A1 20061018 EP 2005-701990 20050121
 EP 1711174 B1 20080319
 AT 389397 T 20080415 AT 2005-701990 20050121
 PRAI GB 2004-1239 A 20040121

✓_{L11} ANSWER 22 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Tetrahedron (2005), 61(27), 6527-6533

✓_{L11} ANSWER 23 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 PA Japan

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005132837	A	✓20050526	JP 2004-296845	20041008
PRAI JP 2003-350926	A	20031009		

✓_{L11} ANSWER 24 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Tetrahedron: Asymmetry ✓ (2004), 15(22), 3635-3642

✓_{L11} ANSWER 25 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Acta Crystallographica, Section E: Structure Reports Online (2004), E60(9), o1463-o1464

✓_{L11} ANSWER 26 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO (2003) 459 pp. Avail.: UMI, Order No. DA3091526


✓_{L11} ANSWER 27 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 SO Tetrahedron: Asymmetry (2003), 14(3), 325-331

L11 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2001:139366 CAPLUS Full-text
 DN 135:335035
 TI Usefulness of nangapiry, a Paraguayan medicinal plant for functional health beverage
 AU Arisawa, Munehisa; Hayashi, Toshimitsu; Momose, Yasunori
 CS Department of Pharmacology, Toyama Medical and Pharmaceutical University, Japan
 SO Food Style 21 (2001), 5(2), 69-73
 CODEN: FSTYFF
 PB Shokuhin Kagaku Shinbunsha
 DT Journal; General Review
 LA Japanese
 AB A review with refs. on the physiol. effect of nangapiry (Eugenia) which is used in Paraguayan health beverage, covering its blood glucose-inhibitory effect, α -glucosidase-inhibitory effect, and blood pressure-lowering effect, etc. The active components in nangapiry, i.e. uniflorine A, uniflorine B, and (+)-(3 α ,4 α ,5 β)-1-methylpiperidine-3,4,5- triol are also disclosed.
 IT 159440-57-6, Uniflorine B 260247-75-4, Uniflorine A
 RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
 (physiol. functions of nangapiry (Eugenia) and its active components)

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-,
(1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 260247-75-4 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-,
(1R,2R,3R,6R,7S,7aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L11 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:897173 CAPLUS [Full-text](#)

DN 135:127011

TI α -Glucosidase inhibitors from Paraguayan natural medicine,
Nangapiry, the leaves of *Eugenia uniflora*

AU Matsumura, Tae; Kasai, Mie; Hayashi, Toshimitsu; Arisawa, Munehisa;
Momose, Yasunori; Arai, Ichiro; Amagaya, Sakae; Komatsu, Yasuhiro

CS Lab. Herbal Garden, Toyama Med. Pharmaceutical Univ., Toyama, 930-0194,
Japan

SO Pharmaceutical Biology (Lisse, Netherlands) (2000), 38(4), 302-307

CODEN: PHBIFC; ISSN: 1388-0209

PB Swets & Zeitlinger B.V.

DT Journal

LA English

AB The water-soluble extract from a Paraguayan natural product, Nangapiry (the leaves of *E. uniflora* (Myrtaceae)), which has been used as an antidiabetic, showed inhibitory activities on the increase of plasma glucose levels in the sucrose tolerance test (STT) in mice. The fraction adsorbed on a cation exchange resin also inhibited α -glucosidases. From the active fraction, 2 new active compds., uniflorine A (I) and B (II) and the known (+)-(3 α ,5 β)-1-methylpiperidine-3,4,5-triol were isolated. The structures of I and II were determined as (-)-(1S,2R,6S,7R,8R,8aR)-1,2,6,7,8-pentahydroxyindolizidine and (+)-(1S,2R,5R,7R,8S,8aS)-1,2,5,7,8-pentahydroxyindolizidine by spectral means, resp.

IT 159440-57-0, Uniflorine B 260247-75-4, Uniflorine A


RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(α -glucosidase inhibitors from Nangapiry (*Eugenia uniflora* leaves) from Paraguay)

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-,
(1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



✓L11 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

TI The total synthesis of (-)-detoxinine and (+)-casuarine using tandem
[4+2]/[3+2] nitroalkene cycloadditions and cycloadditions of nitroethylene

✓L11 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AB Atmospheric pressure chemical ionization (APCI) and electrospray (ES) are compared as ion sources in the anal. of polyhydroxyalkaloids (PHAs) by liquid chromatog. mass spectrometry (LC-MS) and collision induced dissociation (CID) product ion spectra, from tandem mass spectrometry (MS-MS) expts. in a quadrupole ion trap, are reported for 12 naturally occurring PHAs. APCI was found to be a more useful source than ES, as APCI could be used to generate deprotonated mol. ions in neg. mode and for some isomeric PHAs the neg. CID product ion spectra were more diagnostic than the pos. product ion spectra. On-column detection limits were also approx. 32 times lower by pos. APCI than ES. The work provides data that will facilitate screening and characterization of this group of important natural products in plant and fungal exts.

✓L11 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of (+)-Casuarine

L11 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:183992 CAPLUS [Full-text](#)

DN 132:332046

TI New polyhydroxylated pyrrolizidine alkaloids from *Muscari armeniacum*:
structural determination and biological activity

AU Asano, Naoki; Kuroi, Hiroyo; Ikeda, Kyoko; Kizu, Haruhisa; Kameda,
Yukihiko; Kato, Atsushi; Adachi, Isao; Watson, Alison A.; Nash, Robert J.;
Fleet, George W. J.

CS Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa,
920-1181, Japan


SO Tetrahedron: Asymmetry (2000), 11(1), 1-8

CODEN: TASYE3; ISSN: 0957-4166

PB Elsevier Science Ltd.

DT Journal

LA English



- AB Four new polyhydroxypyrrolizidines, hyacinthacines A1, A2, A3 and B3 (I), were isolated from the bulbs of *Muscari armeniacum* (Hyacinthaceae) in addition to the known hyacinthacine C1, which was isolated from *Hyacinthoides non-scripta* (Hyacinthaceae). The structures of hyacinthacines A1, A2, A3 and B3 were identified on the basis of extensive NMR studies as (1S,2R,3R,7aR)-1,2-dihydroxy-3-hydroxymethylpyrrolizidine, (1R,2R,3R,7aR)-1,2-dihydroxy-3-hydroxymethylpyrrolizidine, (1R,2R,3R,5R,7aR)-1,2-dihydroxy-3-hydroxymethyl-5-methylpyrrolizidine and (1S,2R,3R,5R,7R,7aR)-3-hydroxymethyl-5-methyl-1,2,7-trihydroxypyrrolizidine, resp., or the corresponding enantiomers. The inhibitory activities of these new hyacinthacines against a variety of glycosidases are described.

L11 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:150494 CAPLUS [Full-text](#)

DN 132:203147

TI Pentahydroxyindolizidine and α -glucosidase inhibitors containing products of *Eugenia uniflora*

IN Momose, Yasunori

PA Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 2000072770	A	20000307	JP 1998-245307	19980831
PRAI	JP 1998-245307		19980831		

AB (-)-(1S,2R,6S,7R,8R,8aR)-1,2,6,7,8-pentahydroxyindolizidine (I) and (+)-(1S,2R,5R,7R,8S,8aS)-1,2,5,7,8-pentahydroxyindolizidine (II) contained in *E. uniflora* are claimed. Also claimed are α -glucosidase inhibitors containing exts. or powder of *E. uniflora*, useful for treatment of diabetes, obesity, etc. The exts. may contain ≥ 1 selected from I, II, and (+)-(3a,4a,5b)-1-methylpiperidine-3,4,5-triol (III). Isolation of I, II, and III from a hot water extract of *E. uniflora* and their maltase-inhibiting and sucrase-inhibiting activities were shown. The hot water extract (spray-dried powder) was orally administered to mice together with sucrose to significantly suppressed the increase in blood glucose. Pharmaceutical prepsns. containing the exts. were also formulated.

IT 159440-57-QP 269247-75-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(isolation of pentahydroxyindolizidine as α -glucosidase inhibitors from *Eugenia uniflora* for antiobesity and antidiabetic

agents)

RN 159440-57-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-,
(1R,2R,3R,6S,7S,7aR)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 260247-75-4 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-,
(1R,2R,3R,6R,7S,7aR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



✓L11 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
SO Phytochemical Analysis (1999), 10(5), 259-263

✓L11 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis of (+)-Casuarine
SO Organic Letters (1999), 1(8), 1311-1314

L11 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:416453 CAPLUS [Full-text](#)

DN 131:182298

TI Polyhydroxylated pyrrolidine and pyrrolizidine alkaloids from
Hyacinthoides non-scripta and Scilla campanulata

AU Kato, Atsushi; Adachi, Isao; Miyauchi, Miwa; Ikeda, Kyoko; Komae, Tomomi;
Kizu, Haruhisa; Kameda, Yukihiro; Watson, Alison A.; Nash, Robert J.;
Wormald, Mark R.; Fleet, George W. J.; Asano, Naoki

CS Department of Hospital Pharmacy, Toyama Medical and Pharmaceutical
University, Toyama, 930-0194, Japan

SO Carbohydrate Research (1999), 316(1-4), 95-103

CODEN: CRBRAT; ISSN: 0008-6215

PB Elsevier Science Ltd.

DT Journal

LA English

AB Aqueous ethanol exts. from the immature fruits and stalks of bluebell
(Hyacinthoides non-scripta) were subjected to various ion-exchange column

chromatog. steps to give 1,4-dideoxy-1,4-imino-D-arabinitol (I), 2(R),5(R)-bis(hydroxymethyl)-3(R),4(R)-dihydroxypyrrolidine (DMDP) (II), 6-deoxy-6-C-(2,5-dihydroxyhexyl)-DMDP (III), 2,5-dideoxy-2,5-imino-DL-glycero-D-manno-heptitol (homoDMDP) (IV), homoDMDP-7-O-apioside (V), homoDMDP-7-O-β-D-xylopyranoside (VI), (1S*,2R*,3R*,5R*,7aR*)-1,2-dihydroxy-3,5-dihydroxymethylpyrrolizidine (VII), and (1S*,2R*,3R*,5R*,6R*,7R*,7aR*)-3-hydroxymethyl-5-methyl-1,2,6,7-tetrahydroxypyrrolizidine (VIII). Bulbs of *Scilla campanulata* (Hyacinthaceae) yielded (1S*,2R*,3R*,5S*,7aR*)-1,2-dihydroxy-3,5-dihydroxy-methylpyrrolizidine (IX) in addition to compds. I-VII. Compds. III, VI, VII, VIII, and IX are new natural products. Compound IV is a potent competitive inhibitor with Ki values of 1.5 μM for *Caldocellum saccharolyticum* β-glucosidase and 2.2 μM for bovine liver β-galactosidase. The 7-O-β-D-xyloside VI was a stronger competitive inhibitor than IV of *C. saccharolyticum* β-glucosidase and rat intestinal lactase, with Ki values of 0.06 and 0.07 μM, resp., but a weaker inhibitor of bovine liver β-galactosidase. Furthermore, compound IV is also a competitive inhibitor (Ki = 1.8 μM) of porcine kidney trehalase, but 6 was inactive against this enzyme.

IT 240117-30-0E, Hyacinthacine C1

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)


(glycosidase inhibiting activities of pyrrolidine and pyrrolizidine alkaloids from *Hyacinthoides non-scripta* and *Scilla campanulata*)

RN 240117-30-0 CAPLUS

CN 1H-Pyrrolizine-1,2,6,7-tetrol, hexahydro-3-(hydroxymethyl)-5-methyl-, (1S,2R,3R,5R,6R,7R,7aR)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

Currently available stereo shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

✓L11 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN

SO Tetrahedron: Asymmetry (1998), 9(14), 2549-2558

AB The NMR spectra of a number of naturally occurring alexines (tetrahydroxylated pyrrolizidine alkaloids) are analyzed and the consequences of changes in the configuration on the conformation of these bicyclic systems discussed. Unambiguous syntheses of australine (7-epi-alexine) and of 7,7a-epi-alexine have now unequivocally established the structures of two natural products isolated from *Castanospermum australe* which were insecure due to erroneous NMR data. Chemical shift parameters are unreliable as a method of comparing different samples of identical compds.; however, 1H-1H three bond coupling consts. (3JHH) provide easy direct comparison between samples and allow assignments of both the relative configurations for the ring protons and the conformation of the pyrrolizidine framework.

√L11 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
SO Tetrahedron Letters (1997), 38(33), 5869-5872

√L11 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
SO Carbohydrate Letters (1996), 2(3), 169-174

AB The isolation, identification and conformational anal. of Casuarine-6- α -D-glucopyranose I from Casuarina equisetifolia L. and Eugenia jambolana Lam. is reported.

√L11 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2008 ACS on STN
SO Tetrahedron Letters (1994), 35(42), 7849-52

AB The isolation from Casuarina equisetifolia bark of casuarine [(1R,2R,3R,6S,7S,7aR)-3-(hydroxymethyl)-2,6,7-tetrahydroxypyrrolizidine] is reported.

=> log hold

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 06:29:38 ON 22 DEC 2008